For instance, Pembrolizumab and Nivolumab use the Combined Positive Score (CPS) to assess PD-L1 expression in advanced ESCC patients, while Camrelizumab uses the Tumor Proportion Score (TPS). The gene discussed is CD274; the disease is neoplasm.